Post hoc analysis of a trial in 13,165 patients with type 2 diabetes and CVD: a 6-component cardiorenal composite occurred in 23.7% on tirzepatide vs 27.4% on dulaglutide (HR 0.84). GI adverse events were more common with tirzepatide (42.5% vs 35.9%).
Secondary analysisn = 13,165
Nissen et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial